Amgen (NASDAQ: AMGN) reported Q2 EPS of $3.83, $0.29 better than the analyst estimate of $3.54. Revenue for the quarter came in at $6.06 billion versus the consensus estimate of $5.73 billion.

GUIDANCE:

Amgen sees FY2018 EPS of $13.30-$14.00, versus the consensus of $13.75. Amgen sees FY2018 revenue of $22.5-23.2 billion, versus the consensus of $22.59 billion.

Sees CapEx at $750 million

For earnings history and earnings-related data on Amgen (AMGN) click here.

Earnings Guidance

Amgen (AMGN) PT Raised to $179 at BairdJuly 27, 2018 8:48 AM Amgen (AMGN) PT Raised to $205 at Cowen Following 'Beat and Raise'July 27, 2018 8:24 AM Amgen (AMGN) PT Raised to $194 at UBSJuly 27, 2018 7:00 AM Amgen (AMGN) PT Raised to $195 at BarclaysJuly 27, 2018 6:56 AM Amgen (AMGN) PT Raised to $210 at Piper Jaffray Following 2Q July 27, 2018 6:45 AM